Details of the Drug Combination

General Information of Drug Combination (ID: DCZ9V5Z)

Drug Combination Name
PF-03772304 PF-562271
Indication
Disease Entry Status REF
Diffuse large B cell lymphoma Investigative [1]
Component Drugs PF-03772304   DMJ0936 PF-562271   DMSLE03
N.A. Small molecular drug
2D MOL 2D MOL
3D Structure is Not Available
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TMD8
Zero Interaction Potency (ZIP) Score: 29.97
Bliss Independence Score: 31.16
Loewe Additivity Score: 5.27
LHighest Single Agent (HSA) Score: 6.49

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of PF-03772304
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [2]
PF-03772304 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [2]
PI3-kinase gamma (PIK3CG) TTHBTOP PK3CG_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of PF-562271
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
PF-562271 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Focal adhesion kinase 1 (FAK) TTON5IT FAK1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett. 2012 Nov 7;4(1):91-7.
3 ClinicalTrials.gov (NCT00666926) Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms. U.S. National Institutes of Health.
4 Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45.